{"organizations": [], "uuid": "1a179cc9f82fe70071743f2a616f9c7b1254ec34", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 1, "shares": 1, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2018/05/29/105237311-GettyImages-469934403.1910x1000.jpg", "site_section": "", "section_title": "", "url": "https://www.cnbc.com/2018/05/29/novo-nordisks-oral-diabetes-drug-beats-jardiance-in-study.html", "country": "US", "domain_rank": 767, "title": "Novo Nordisk's oral diabetes drug beats Jardiance in study", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.819, "site_type": "news", "published": "2018-05-29T03:00:00.000+03:00", "replies_count": 0, "uuid": "1a179cc9f82fe70071743f2a616f9c7b1254ec34"}, "author": "Jean-Francois Monier", "url": "https://www.cnbc.com/2018/05/29/novo-nordisks-oral-diabetes-drug-beats-jardiance-in-study.html", "ord_in_thread": 0, "title": "Novo Nordisk's oral diabetes drug beats Jardiance in study", "locations": [], "entities": {"persons": [{"name": "jardiance", "sentiment": "negative"}, {"name": "jean-francois monier", "sentiment": "none"}], "locations": [], "organizations": [{"name": "novo nordisk", "sentiment": "negative"}, {"name": "eli lilly", "sentiment": "none"}, {"name": "boehringer ingelheim", "sentiment": "none"}, {"name": "novo", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Drugs Novo Nordisk's oral diabetes drug beats Jardiance in study Novo Nordisk's experimental diabetes pill proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance. Novo hopes to launch the once-daily pill in 2020. The pill would simulate insulin production as part of the company's blockbuster movement to make insulin intake more convenient. Published 3 Hours Ago Reuters Jean-Francois Monier | AFP | Getty Images An employee wearing a protective uniform works on a production line of insulin at a factory of Novo Nordisk.\nAn experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.\nThe success of oral semaglutide in the Phase III trial is a boost for a medicine seen as important for ensuring the group's long-term growth in a highly competitive diabetes market.\nThe once-daily pill, which Novo hopes to launch in 2020, belongs to a blockbuster class of treatments known as GLP-1s that stimulate insulin production. So far, all have been injections and a pill would offer a step-change in convenience.\nMads Krogsgaard Thomsen, Novo's chief science officer, said the positive results from the so-called PIONEER 2 trial were \"an important milestone\" in the clinical development of oral semaglutide. Related Securities ", "external_links": [], "published": "2018-05-29T03:00:00.000+03:00", "crawled": "2018-05-30T00:37:51.000+03:00", "highlightTitle": ""}